Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERSCoV infection in a nonhuman primate model of common marmoset

Journal of Infectious Diseases

Volumn 212, Issue 12, 2015, Pages 1904-1913

  Chan, Jasper Fuk Woo ^a,b   Yao, Yanfeng ^c   Yeung, Man Lung ^b   Deng, Wei ^c   Bao, Linlin ^c   Jia, Lilong ^b   Li, Fengdi ^c   Xiao, Chong ^c   Gao, Hong ^c   Yu, Pin ^c   Cai, Jian Piao ^b   Chu, Hin ^b   Zhou, Jie ^b   Chen, Honglin ^a,b   Qin, Chuan ^c   Yuen, Kwok Yung ^a,b  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

Author keywords

Animal; Common marmoset; Coronavirus; Interferon; Kaletra; Lopinavir; MERS; Mycophenolate; Primate; Treatment

Indexed keywords

BETA1 INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LOPINAVIR PLUS RITONAVIR; MYCOPHENOLATE MOFETIL; ANTIVIRUS AGENT; BETA INTERFERON; LOPINAVIR; RITONAVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALLITHRIX JACCHUS; CONTROLLED STUDY; CORONAVIRUS INFECTION; DRUG REPOSITIONING; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTERSTITIAL PNEUMONIA; LUNG INFILTRATE; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MORTALITY RATE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; ANIMAL; CALLITHRIX; CORONAVIRUS INFECTIONS; DISEASE MODEL; ISOLATION AND PURIFICATION; PATHOLOGY; SURVIVAL;

ANIMALS; ANTIVIRAL AGENTS; CALLITHRIX; CORONAVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; DRUG REPOSITIONING; INTERFERON-BETA; LOPINAVIR; MALE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; RITONAVIR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84955391557     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv392     Document Type: Article

References (50)

1. Chan JF, To KK, Tse H, Jin DY, Yuen KY. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Micro-biol 2013; 21:544-55.
2. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367:1814-20.
3. Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 2015; 28:465-522.
4. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13:752-61.
5. Chan JF, Li KS, To KK, Cheng VC, Chen H, Yuen KY. Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic? J Infect 2012; 65:477-89.
6. Jiang L, Wang N, Zuo T, et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycopro-tein. Sci Transl Med 2014; 6:234ra59.
7. Lu L, Liu Q, Zhu Y, et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun 2014; 5:3067.
8. Gao J, Lu G, Qi J, et al. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J Virol 2013; 87:13134-40.
9. Du L, Zhao G, Yang Y, et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol 2014; 88:7045-53.
10. Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004; 10:676-8.
11. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24:44-6.
12. Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52:447-56.
13. Yang ZY, Werner HC, Kong WP, et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci USA 2005; 102:797-801.
14. Weingartl H, Czub M, Czub S, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 2004; 78:12672-6.
15. Chan JF, Chan KH, Kao RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013; 67:606-16.
16. Dyall J, Coleman CM, Hart BJ, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 2014; 58:4885-93.
17. de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 2014; 58:4875-84.
18. Kindrachuk J, Ork B, Hart BJ, et al. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Chemother 2015; 59:1088-99.
19. Liu Q, Xia S, Sun Z, et al. Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. Antimicrob Agents Chemother 2015; 59:742-4.
20. Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin. Sci Rep 2013; 3:1686.
21. Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013; 19:1313-7.
22. Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 2014; 14:1090-5.
23. Falzarano D, de Wit E, Feldmann F, et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLOS Pathog 2014; 10:e1004250.
24. Chan JF, Choi GK, Tsang AK, et al. Development and evaluation of novel real-time RT-PCR assays with locked nucleic acid probes targeting the leader sequences of human pathogenic coronaviruses. J Clin Mi-crobiol 2015; 53:2722-6.
25. Zhou J, Chu H, Li C, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cyto-kines and chemokines in human macrophages: implications for patho-genesis. J Infect Dis 2014; 209:1331-42.
26. Chu H, Zhou J, Wong BH, et al. Middle East respiratory syndrome co-ronavirus efficiently infects human primary T lymphocytes and activates both the extrinsic and intrinsic apoptosis pathways [Epub ahead of print]. J Infect Dis 2015; doi:10.1093/infdis/jiv380.
27. Chan JF, Chan KH, Choi GK, et al. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J Infect Dis 2013; 207:1743-52.
28. Chan KH, Chan JF, Tse H, et al. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J Infect 2013; 67:130-40.
29. Yao Y, Bao L, Deng W, et al. An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus. J Infect Dis 2014; 209:236-42.
30. Ishimatsu M, Suzuki H, Akiyama H, Miura T, Hayami M, Ido E. Construction of a novel SHIV having an HIV-1-derived protease gene and its infection to rhesus macaques: a useful tool for in vivo efficacy tests of protease inhibitors. Microbes Infect 2007; 9:475-82.
31. Genentech USA, Inc. Product Information: CellCept®. http://www.gene. com/download/pdf/cellcept-prescribing.pdf. Accessed 10 June 2015.
32. Bayer Australia Limited. Product Information: Betaferon® Single use pack drug. http://www.bayerresources.com.au/resources/uploads/PI/file9314.pdf. Accessed 10 June 2015.
33. Chu H, Zhou J, Wong BH, et al. Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. Virology 2014; 454-455:197-205.
34. Raj VS, Smits SL, Provacia LB, et al. Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus. J Virol 2014; 88:1834-8.
35. de Wit E, Prescott J, Baseler L, et al. The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLOS One 2013; 8:e69127.
36. Coleman CM, Matthews KL, Goicochea L, Frieman MB. Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J Gen Virol 2014; 95(Pt 2):408-12.
37. Zhao J, Li K, Wohlford-Lenane C, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA 2014; 111:4970-5.
38. Agrawal AS, Garron T, Tao X, et al. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol 2015; 89:3659-70.
39. Faure E, Poissy J, Goffard A, et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLOS One 2014; 9:e88716.
40. AlGhamdi M, Mushtaq F, Awn N, Shalhoub S. MERS CoV infection in two renal transplant recipients: case report. Am J Transplant 2015; 15:1101-4.
41. Rizza SA, Badley AD. HIV protease inhibitors impact on apoptosis. Med Chem 2008; 4:75-9.
42. Abbott Laboratories. Product Information: Kaletra®. http://hivdb.stanford. edu/pages/linksPages/LPV-RTV-PI.pdf. Accessed 10 June 1015.
43. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59:252-6.
44. Spanakis N, Tsiodras S, Haagmans BL, et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents 2014; 44:528-32.
45. Lau SK, Lau CC, Chan KH, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for patho-genesis and treatment. J Gen Virol 2013; 94:2679-90.
46. de Wilde AH, Raj VS, Oudshoorn D, et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment. J Gen Virol 2013; 94:1749-60.
47. Hart BJ, Dyall J, Postnikova E, et al. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome corona-virus in cell-based assays. J Gen Virol 2014; 95:571-7.
48. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and inter-feron therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 2014; 20:42-6.
49. Khalid M, Al Rabiah F, Khan B, Al Mobeireek A, Butt TS, Al Mutairy E. Ribavirin and interferon (IFN)-alpha-2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus (MERS-CoV): a preliminary report of two cases. Antivir Ther 2015; 20:87-91.
50. Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-alpha2a or IFN-beta1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother 2015; 70:2129-32.